Exchange: NASDAQ·Updated 01:32 AM EDT
News
all
press releases
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.
Stocktwits
More News
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an annualized basis producing an average annual return of 49.25%. Currently, Revolution Medicines has a marketread more...
Benzinga
RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill — Is Drug Price Overshadowing Approval?
The Food and Drug Administration (FDA) cleared the once-daily tablet, Rasonque, for certain adults with metastatic pancreatic adenocarcinoma.
Stocktwits
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug
FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs chemotherapy.read more...
Benzinga
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers...
CNBC: Top News
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't...
Yahoo! Finance: News
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
Why Revolution Medicines May Be Big Pharma's Next Takeover Target...
Yahoo! Finance: News
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including...
Business Wire
Here's How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a marketread more...
Benzinga

Advertisement|Remove ads.